Swiss National Bank raised its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Rating) by 1.7% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 332,600 shares of the biopharmaceutical company’s stock after buying an additional 5,500 shares during the period. Swiss National Bank owned about 0.25% of Halozyme Therapeutics worth $18,925,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also modified their holdings of the stock. Financial Gravity Asset Management Inc. acquired a new stake in Halozyme Therapeutics during the third quarter valued at $2,220,000. Cullen Frost Bankers Inc. purchased a new stake in shares of Halozyme Therapeutics during the 3rd quarter worth about $40,000. Harvest Fund Management Co. Ltd acquired a new stake in shares of Halozyme Therapeutics during the 4th quarter valued at about $57,000. Almanack Investment Partners LLC. bought a new stake in shares of Halozyme Therapeutics in the 3rd quarter valued at approximately $55,000. Finally, Wipfli Financial Advisors LLC acquired a new position in Halozyme Therapeutics in the third quarter worth approximately $60,000. 96.32% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
A number of analysts have issued reports on HALO shares. SVB Leerink cut shares of Halozyme Therapeutics from an “outperform” rating to a “market perform” rating and set a $42.00 target price for the company. in a research note on Thursday, March 16th. StockNews.com initiated coverage on shares of Halozyme Therapeutics in a report on Thursday, March 16th. They issued a “hold” rating for the company. SVB Securities lowered Halozyme Therapeutics from an “outperform” rating to a “market perform” rating and set a $42.00 target price on the stock. in a report on Thursday, March 16th. Piper Sandler upgraded Halozyme Therapeutics from a “neutral” rating to an “overweight” rating and set a $46.00 price target for the company in a research note on Wednesday. Finally, JMP Securities reissued a “market outperform” rating and issued a $66.00 price objective (up from $62.00) on shares of Halozyme Therapeutics in a research note on Wednesday, February 22nd. Three analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat, Halozyme Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $55.30.
Halozyme Therapeutics Stock Down 0.0 %
Halozyme Therapeutics (NASDAQ:HALO – Get Rating) last released its earnings results on Tuesday, February 21st. The biopharmaceutical company reported $0.44 EPS for the quarter, beating the consensus estimate of $0.43 by $0.01. The firm had revenue of $181.50 million during the quarter, compared to analysts’ expectations of $186.07 million. Halozyme Therapeutics had a net margin of 30.62% and a return on equity of 141.30%. On average, equities analysts predict that Halozyme Therapeutics, Inc. will post 2.41 EPS for the current year.
Insider Activity at Halozyme Therapeutics
In related news, SVP Michael J. Labarre sold 10,000 shares of the business’s stock in a transaction dated Tuesday, April 18th. The stock was sold at an average price of $36.00, for a total transaction of $360,000.00. Following the transaction, the senior vice president now directly owns 141,911 shares in the company, valued at $5,108,796. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, SVP Michael J. Labarre sold 10,000 shares of the firm’s stock in a transaction on Tuesday, April 18th. The stock was sold at an average price of $36.00, for a total value of $360,000.00. Following the completion of the transaction, the senior vice president now directly owns 141,911 shares of the company’s stock, valued at $5,108,796. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Nicole Labrosse sold 2,525 shares of the business’s stock in a transaction on Thursday, February 16th. The shares were sold at an average price of $49.26, for a total transaction of $124,381.50. Following the completion of the sale, the chief financial officer now directly owns 9,066 shares in the company, valued at approximately $446,591.16. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 73,586 shares of company stock worth $3,367,746. Company insiders own 2.40% of the company’s stock.
About Halozyme Therapeutics
Halozyme Therapeutics, Inc operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
Featured Stories
- Get a free copy of the StockNews.com research report on Halozyme Therapeutics (HALO)
- An Updraft Is Brewing For DraftKings
- PepsiCo Hits “Sweet Spot” For APAC Growth, Macros Agree
- High-Risk Mullen Automotive Continues To Build Momentum
- 3 Recession-Proof Stocks With Nice Dividends
- Oracle Stock Climbs For Third Month, Still In Buy Range
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
